|
FRCP (N = 21)
|
FSCa (N = 19)
|
P value
|
---|
Age (years) - median (range)
|
70 (23–91)
|
76 (35–90)
|
0.311
|
Gender female - n (%)
|
7 (33.3)
|
8 (42.1)
|
0.567
|
Time to candidemia – median/range
|
22 (0–83)
|
25 (7–134)
|
0.185
|
Apache II score – median/range
|
14 (3–29)
|
16 (3–30)
|
0.138
|
Death up to 30 days after candidemia (%)
|
9 (42.9)
|
9 (47.4)
|
0.78
|
Comorbidities - n (%)
|
Cancer
|
5 (23.8)
|
2 (10.5)
|
0.270
|
Pulmonary disease
|
9 (42.9)
|
11 (57.9)
|
0.342
|
Cardiac disease
|
6 (28.6)
|
3 (15.8)
|
0.557
|
Diabetes mellitusb
|
11 (52.4)
|
2 (10.5)
|
0.013
|
Renal failure
|
4 (19.0)
|
3 (15.8)
|
1.000
|
Previous exposure to medical procedures and medicines - n (%)
|
Short-term catheter
|
21 (100.0)
|
17 (89.5)
|
0.424
|
Catheter tip positive
|
4 (19.0)
|
3 (15.8)
|
1.000
|
Previous hemodialysis
|
3 (14.3)
|
1 (5.3)
|
0.673
|
Prior surgery
|
12 (61.9)
|
10 (52.6)
|
0.775
|
Mechanical ventilation
|
15 (71.4)
|
14 (73.7)
|
0.873
|
Parenteral nutrition
|
7 (33.3)
|
1 (5.3)
|
0.059
|
Previous Hospitalization
|
4 (19)
|
8 (42.1)
|
0.112
|
Antibiotics
|
10 (47.6)
|
8 (42.1)
|
0.726
|
Steroids
|
8 (38.1)
|
7 (36.8)
|
0.942
|
Any antifungal drug
|
7 (33.3)
|
3 (15.8)
|
0.361
|
Fluconazole
|
4 (19.0)
|
3 (15.8)
|
1.000
|
-
aall Candida strains considered susceptible to fluconazole by the Vitek 2 system. bvariable identified as independent factor associated with infection by FRCP